508 related articles for article (PubMed ID: 34972975)
21. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
22. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular toxicities associated with immune checkpoint inhibitors.
Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
[TBL] [Abstract][Full Text] [Related]
24. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J
Front Immunol; 2022; 13():1006860. PubMed ID: 36189211
[TBL] [Abstract][Full Text] [Related]
25. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
26. Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
Sharma A; Alexander G; Chu JH; Markopoulos A; Maloul G; Ayub MT; Fidler MJ; Okwuosa TM
J Am Heart Assoc; 2024 May; 13(10):e032620. PubMed ID: 38761070
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity.
Zatarain-Nicolás E; Martín P; Márquez Rodas I; Virizuela J; Martín García A; Mitroi C; Cosín Sales J; Barrios V; Sánchez-Cabo F; Ibañez B; de Castro Carpeño J; López Fernández T
Clin Transl Oncol; 2023 Nov; 25(11):3073-3085. PubMed ID: 37227656
[TBL] [Abstract][Full Text] [Related]
28. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
29. A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer.
Hu Y; Liu C; Jin S; Yi Z; Wang C; Pan X; Huang H
BMC Pulm Med; 2023 Apr; 23(1):119. PubMed ID: 37060029
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy.
Delombaerde D; Vervloet D; Franssen C; Croes L; Gremonprez F; Prenen H; Peeters M; Vulsteke C
ESMO Open; 2021 Aug; 6(4):100216. PubMed ID: 34271309
[TBL] [Abstract][Full Text] [Related]
31. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
32. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature.
Boutros A; Bottini A; Rossi G; Tanda ET; Spagnolo F; Barletta G; Croce E; Fava P; Parisi A; De Rosa F; Palla M; Marconcini R; Ferrari M; Grandis M; Spallarossa P; Sarocchi M; Arboscello E; Del Mastro L; Lambertini M; Pronzato P; Genova C
ESMO Open; 2023 Feb; 8(1):100791. PubMed ID: 36791639
[TBL] [Abstract][Full Text] [Related]
33. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
34. Cardiotoxicity danger in immunotherapy.
Jagielska B; Ozdowska P; Gepner K; Kubala S; Siedlecki JA; Sarnowski TJ; Sarnowska E
IUBMB Life; 2020 Jun; 72(6):1160-1167. PubMed ID: 32359132
[TBL] [Abstract][Full Text] [Related]
35. Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report.
Liu S; Ma G; Wang H; Yu G; Chen J; Song W
Medicine (Baltimore); 2022 Nov; 101(46):e31873. PubMed ID: 36401466
[TBL] [Abstract][Full Text] [Related]
36. [Call for attention to the scientific issues in cardiovascular adverse effects associated with immune checkpoint inhibitors].
Zhang ZR
Zhonghua Yi Xue Za Zhi; 2023 Nov; 103(42):3328-3331. PubMed ID: 37963733
[TBL] [Abstract][Full Text] [Related]
37. Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors.
van der Vegt SA; Polonchuk L; Wang K; Waters SL; Baker RE
J Theor Biol; 2022 Mar; 537():111002. PubMed ID: 35007511
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis.
Inno A; Tarantini L; Parrini I; Spallarossa P; Maurea N; Bisceglia I; Silvestris N; Russo A; Gori S
Curr Oncol Rep; 2023 Jul; 25(7):743-751. PubMed ID: 37017825
[TBL] [Abstract][Full Text] [Related]
39. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
Wei SC; Meijers WC; Axelrod ML; Anang NAS; Screever EM; Wescott EC; Johnson DB; Whitley E; Lehmann L; Courand PY; Mancuso JJ; Himmel LE; Lebrun-Vignes B; Wleklinski MJ; Knollmann BC; Srinivasan J; Li Y; Atolagbe OT; Rao X; Zhao Y; Wang J; Ehrlich LIR; Sharma P; Salem JE; Balko JM; Moslehi JJ; Allison JP
Cancer Discov; 2021 Mar; 11(3):614-625. PubMed ID: 33257470
[TBL] [Abstract][Full Text] [Related]
40. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis.
Cau R; Solinas C; De Silva P; Lambertini M; Agostinetto E; Scartozzi M; Montisci R; Pontone G; Porcu M; Saba L
Int J Cancer; 2022 Dec; 151(11):1860-1873. PubMed ID: 35730658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
